Kassouf Wassim, Sanchez-Ortiz Ricardo, Tamboli Pheroze, Tannir Nizar, Jonasch Eric, Merchant Madhur M, Matin Surena, Swanson David A, Wood Christopher G
Division of Urology, McGill University Health Center, Montreal, Quebec, Canada.
J Urol. 2007 Nov;178(5):1896-900. doi: 10.1016/j.juro.2007.07.037. Epub 2007 Sep 17.
To our knowledge the benefit of cytoreductive surgery for patients with metastatic renal cell carcinoma with nonclear cell histology is unknown. In this retrospective study we report our experience with cytoreductive nephrectomy for nonclear cell metastatic renal cell carcinoma at M. D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma.
From 1991 to 2006, 606 patients with metastatic renal cell carcinoma underwent cytoreductive nephrectomy and they formed the basis of this report. Of these patients 92 had nonclear cell metastatic renal cell carcinoma. The remaining 514 patients had clear cell metastatic renal cell carcinoma and they formed a comparative group. Multivariate Cox regression analysis was performed to evaluate the relationship between clinical variables and histology (clear cell vs nonclear cell) on disease specific survival.
Compared with patients with clear cell histology those with nonclear cell metastatic renal cell carcinoma were younger (p = 0.0001), and more likely to have nodal metastases (p <0.0001) and sarcomatoid features (23% vs 13%, p = 0.026). On multivariate analysis median disease specific survival in patients with nonclear cell histology was significantly worse than that in patients with clear cell metastatic renal cell carcinoma (9.7 vs 20.3 months, p = 0.0003) even after adjusting for T stage, grade, performance status, age and sarcomatoid features. Sarcomatoid features were a predictor of poor outcome in cases of clear and nonclear cell histology, although even in the absence of sarcomatoid features nonclear cell histology was associated with worse disease specific survival (p = 0.017). Interestingly although there was a significantly higher incidence of positive nodes in patients with nonclear histology (p <0.0001), this phenotype was not associated with a worse disease specific survival, as it was in those with clear cell histology (p = 0.0001). In fact, patients with node negative disease with nonclear cell histology had the worst prognosis overall in the entire group.
Patients with nonclear cell metastatic renal cell carcinoma were younger and had a higher incidence of nodal metastases, a higher incidence of sarcomatoid features and a worse prognosis than those with clear cell histology who underwent cytoreductive surgery.
据我们所知,减瘤手术对非透明细胞组织学类型的转移性肾细胞癌患者的益处尚不清楚。在这项回顾性研究中,我们报告了在MD安德森癌症中心对非透明细胞转移性肾细胞癌进行减瘤性肾切除术的经验。我们将结果与透明细胞转移性肾细胞癌患者的结果进行了比较。
1991年至2006年,606例转移性肾细胞癌患者接受了减瘤性肾切除术,他们构成了本报告的基础。在这些患者中,92例患有非透明细胞转移性肾细胞癌。其余514例患者患有透明细胞转移性肾细胞癌,他们构成了一个对照组。进行多变量Cox回归分析以评估临床变量与组织学(透明细胞与非透明细胞)对疾病特异性生存的关系。
与透明细胞组织学类型的患者相比,非透明细胞转移性肾细胞癌患者更年轻(p = 0.0001),更可能有淋巴结转移(p <0.0001)和肉瘤样特征(23%对13%,p = 0.026)。多变量分析显示,即使在调整了T分期、分级、体能状态、年龄和肉瘤样特征后,非透明细胞组织学类型患者的疾病特异性生存中位数仍显著低于透明细胞转移性肾细胞癌患者(9.7个月对20.3个月,p = 0.0003)。肉瘤样特征是透明细胞和非透明细胞组织学类型病例预后不良的预测因素,尽管即使没有肉瘤样特征,非透明细胞组织学类型也与更差的疾病特异性生存相关(p = 0.017)。有趣的是,尽管非透明组织学类型患者的阳性淋巴结发生率显著更高(p <0.0001),但这种表型与疾病特异性生存较差无关,而在透明细胞组织学类型患者中则与较差的疾病特异性生存相关(p = 0.0001)。事实上,非透明细胞组织学类型的淋巴结阴性疾病患者在整个组中的总体预后最差。
与接受减瘤手术的透明细胞组织学类型患者相比,非透明细胞转移性肾细胞癌患者更年轻,淋巴结转移发生率更高,肉瘤样特征发生率更高,预后更差。